

Aimee L Jackson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4208841/aimee-l-jackson-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36

papers

9,968

citations

26

h-index

36

g-index

36

ext. papers

10,714

ext. citations

11.6

avg, IF

5.7

L-index

#	Paper	IF	Citations
36	A microRNA component of the p53 tumour suppressor network. <i>Nature</i> , 2007 , 447, 1130-4	50.4	2264
35	Expression profiling reveals off-target gene regulation by RNAi. <i>Nature Biotechnology</i> , 2003 , 21, 635-7	44.5	1857
34	Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 57-67	64.1	699
33	Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. <i>Rna</i> , 2006 , 12, 1179-87	5.8	681
32	Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. <i>Rna</i> , 2006 , 12, 1197-205	5.8	593
31	MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. <i>Molecular and Cellular Biology</i> , 2008 , 28, 2167-74	4.8	480
30	Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. <i>Molecular and Cellular Biology</i> , 2007 , 27, 2240-52	4.8	462
29	The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2001 , 477, 7-21	3.3	452
28	Minimizing the risk of reporting false positives in large-scale RNAi screens. <i>Nature Methods</i> , 2006 , 3, 777-9.6	9.6	362
27	Noise amidst the silence: off-target effects of siRNAs?. <i>Trends in Genetics</i> , 2004 , 20, 521-4	8.5	298
26	Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. <i>Cancer Research</i> , 2008 , 68, 10105-12	10.1	292
25	Genome-scale RNAi profiling of cell division in human tissue culture cells. <i>Nature Cell Biology</i> , 2007 , 9, 1401-12	23.4	254
24	The mutation rate and cancer. <i>Genetics</i> , 1998 , 148, 1483-90	4	164
23	Myc-regulated microRNAs attenuate embryonic stem cell differentiation. <i>EMBO Journal</i> , 2009 , 28, 3157-70	10.6	159
22	Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. <i>Molecular and Cellular Biology</i> , 2006 , 26, 9377-86	4.8	159
21	Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. <i>Nature Methods</i> , 2007 , 4, 337-44	21.6	151
20	Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 183, 428-444	4.5	129

19	A MicroRNA-29 Mimic (Replarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 1073-1081	4.3	80
18	Safety assessment of food and feed from biotechnology-derived crops employing RNA-mediated gene regulation to achieve desired traits: a scientific review. <i>Regulatory Toxicology and Pharmacology</i> , 2013 , 66, 167-76	3.4	74
17	MicroRNA-like off-target transcript regulation by siRNAs is species specific. <i>Rna</i> , 2009 , 15, 308-15	5.8	64
16	Cdc7 protein kinase for DNA metabolism comes of age. <i>Molecular Microbiology</i> , 1994 , 11, 805-10	4.1	50
15	Developing microRNA therapeutics: approaching the unique complexities. <i>Nucleic Acid Therapeutics</i> , 2012 , 22, 213-25	4.8	49
14	On the origin of multiple mutations in human cancers. <i>Seminars in Cancer Biology</i> , 1998 , 8, 421-9	12.7	42
13	Microsatellite instability induced by hydrogen peroxide in Escherichia coli. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2000 , 447, 187-98	3.3	41
12	Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth and. <i>Clinical Cancer Research</i> , 2021 , 27, 1139-1149	12.9	35
11	Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene. <i>Respiratory Research</i> , 2012 , 13, 92	7.3	27
10	The Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent. <i>Molecular Therapy</i> , 2017 , 25, 694-704	11.7	16
9	How will RNAi facilitate drug development?. <i>Science Signaling</i> , 2005 , 2005, pe39	8.8	11
8	Origin of multiple mutations in human cancers. <i>Drug Metabolism Reviews</i> , 1998 , 30, 285-304	7	7
7	Effect of Xpcl1 activation and p27(Kip1) loss on gene expression in murine lymphoma. <i>PLoS ONE</i> , 2011 , 6, e14758	3.7	5
6	A multiplexed siRNA screening strategy to identify genes in the PARP pathway. <i>Journal of Biomolecular Screening</i> , 2012 , 17, 1316-28		4
5	Chromosome 20q amplification regulates in vitro response to Kinesin-5 inhibitor. <i>Cancer Informatics</i> , 2008 , 6, 147-64	2.4	3
4	Reflections on microRNAs in chronic pulmonary disease: looking into the miR-ror and crystal ball. <i>Inflammation and Allergy: Drug Targets</i> , 2013 , 12, 88-98		3
3	Hidden reach of the micromanagers. <i>BMC Biology</i> , 2010 , 8, 53	7.3	1
2	OXIDANTS AND MULTIPLE MUTATIONS IN CANCER. <i>Biochemical Society Transactions</i> , 1996 , 24, 522S-523S		1

1 Mechanisms of Oligonucleotide Actions **2018**, 1-37